Galapagos NV has completed first-in-human trials with GLPG0555 in healthy volunteers in its arthritis alliance with GlaxoSmithKline. Galapagos also initiated Phase I development for a second drug candidate, GLPG0778, triggering a milestone payment of $9.6 million. Initial Phase I results for GLPG0555 showed no changes in vital signs and lab parameters for dosing up to 14 consecutive days in healthy volunteers and the drug was well tolerated with no severe adverse events reported. In December ...